Randomized controlled trials for influenza drugs and vaccines: A review of controlled human infection studies

International Journal of Infectious Diseases

Volumn 49, Issue , 2016, Pages 18-29

  Balasingam, Shobana ^a   Wilder Smith, Annelies ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Challenge studies; Controlled human infection; Influenza; Influenza therapeutics; Influenza vaccine; Randomized controlled trials

Indexed keywords

ANTIVIRUS AGENT; INFLUENZA VACCINE;

COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; INCIDENCE; INFECTION RATE; INFLUENZA; META ANALYSIS; MULTICENTER STUDY (TOPIC); NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRUS SHEDDING; IMMUNOLOGY; INFLUENZA, HUMAN; METHODOLOGY;

ANTIVIRAL AGENTS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84975517375     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2016.05.013     Document Type: Review

References (64)

1. Pollard A.J., Savulescu J., Oxford J., Hill A.V., Levine M.M., Lewis D.J., et al. Human microbial challenge: the ultimate animal model. Lancet Infect Dis 2012, 12:903-905. 10.1016/S1473-3099(12)70292-X.
2. Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent) 2005, 18:21-25.
3. Balasingam S., Horby P., Wilder-Smith A. The potential for a controlled human infection platform in Singapore. Singapore Med J 2014, 55:456-461.
4. Belser J.A., Katz J.M., Tumpey T.M. The ferret as a model organism to study influenza A virus infection. Dis Model Mech 2011, 4:575-579. 10.1242/dmm.007823.
5. Thangavel R.R., Bouvier N.M. Animal models for influenza virus pathogenesis, transmission, and immunology. J Immunol Methods 2014, 410:60-79. 10.1016/j.jim.2014.03.023.
6. Smorodintseff AA, Tushinsky MD, Drobyshevskaya I, Karolin AA, Osetroff AI. Investigation of volunteers infected with the influenza virus. Am J Med Sci 1937;194:159-70.
7. Treanor JJ. Volunteer challenge studies. In: Nicolson KG WR, Hay AJ, editors. Textbook of influenza. Oxford: Blackwell Science; 1998, p. 517-37.
8. Francis T., Salk J.E., Pearson H.E., Brown P.N. Protective effect of vaccination against induced influenza A. J Clin Invest 1945, 24:536-546. 10.1172/jci101633.
9. Salk J.E., Pearson H.E., Brown P.N., Francis T. Protective effect of vaccination against induced influenza B. J Clin Invest 1945, 24:547-553. 10.1172/jci101634.
10. Henle W., Henle G., Stokes J. Demonstration of the efficacy of vaccination against influenza type A by experimental infection of human beings. J Immunol 1943, 46:163-175.
11. Burnet FM, Foley M. The results of intranasal inoculation of modified and unmodified influenza virus strains in human volunteers. Med J Aust 1940;2:655-9.
12. Burnet F.M. Influenza virus B: II. Immunization of human volunteers with living attenuated virus. Med J Aust 1942, 1:673-674.
13. Burnet F.M. Immunization against epidemic influenza with living and attenuated virus. Med J Aust 1943, 1:385-389.
14. Clements M.L., Betts R.F., Murphy B.R. Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. Lancet 1984, 1:705-708.
15. Jackson GG, Muldoon RL, Akers LW. Serological evidence for prevention of influenza infection in volunteers by an anti-influenzal drug adamantanamine hydrochloride. Antimicrob Agents Chemother 1963;161:703-7.
16. Hayden F.G., Zylidnikov D.M., Iljenko V.I., Padolka Y.V. Comparative therapeutic effect of aerosolized and oral rimantadine HCl in experimental human influenza A virus infection. Antiviral Res 1982, 2:147-153.
17. Merigan T.C., Reed S.E., Hall T.S., Tyrrell D.A. Inhibition of respiratory virus infection by locally applied interferon. Lancet 1973, 1:563-567.
18. Hayden F.G. Experimental human influenza: observations from studies of influenza antivirals. Antivir Ther 2012, 17(1 Pt B):133-141. 10.3851/IMP2062.
19. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
20. Hayden F.G., Treanor J.J., Fritz R.S., Lobo M., Betts R.F., Miller M., et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999, 282:1240-1246.
21. Al-Nakib W., Higgins P.G., Willman J., Tyrrell D.A., Swallow D.L., Hurst B.C., et al. Prevention and treatment of experimental influenza A virus infection in volunteers with a new antiviral ICI 130,685. J Antimicrob Chemother 1986, 18:119-129.
22. Jones S., Evans K., McElwaine-Johnn H., Sharpe M., Oxford J., Lambkin-Williams R., et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine 2009, 27:2506-2512. 10.1016/j.vaccine.2009.02.061.
23. Ramos E.L., Mitcham J.L., Koller T.D., Bonavia A., Usner D.W., Balaratnam G., et al. Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza. J Infect Dis 2015, 211:1038-1044. 10.1093/infdis/jiu539.
24. Fritz R.S., Hayden F.G., Calfee D.P., Cass L.M., Peng A.W., Alvord W.G., et al. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis 1999, 180:586-593. 10.1086/314938.
25. Barroso L., Treanor J., Gubareva L., Hayden F.G. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther 2005, 10:901-910.
26. Reuman P.D., Bernstein D.I., Keefer M.C., Young E.C., Sherwood J.R., Schiff G.M. Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A. Antiviral Res 1989, 11:27-40.
27. Treanor J.J., Kotloff K., Betts R.F., Belshe R., Newman F., Iacuzio D., et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 1999, 18:899-906.
28. Doyle W.J., Skoner D.P., Alper C.M., Allen G., Moody S.A., Seroky J.T., et al. Effect of rimantadine treatment on clinical manifestations and otologic complications in adults experimentally infected with influenza A (H1N1) virus. J Infect Dis 1998, 177:1260-1265.
29. Hayden F.G., Treanor J.J., Betts R.F., Lobo M., Esinhart J.D., Hussey E.K. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996, 275:295-299.
30. Hayden F.G., Jennings L., Robson R., Schiff G., Jackson H., Rana B., et al. Oral oseltamivir in human experimental influenza B infection. Antivir Ther 2000, 5:205-213.
31. Calfee D.P., Peng A.W., Cass L.M., Lobo M., Hayden F.G. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother 1999, 43:1616-1620.
32. Betts R.F., Douglas R.G., Roth F.K., Little J.W. Efficacy of live attenuated influenza A/Scotland/74 (H3N2) virus vaccine against challenge with influenza A/Victoria/3/75 (H3N2) virus. J Infect Dis 1977, 136:746-753.
33. Hayden F.G., Tunkel A.R., Treanor J.J., Betts R.F., Allerheiligen S., Harris J. Oral LY217896 (1,3,4-thiadiazol-2-ylcyanamide) for prevention of experimental influenza A virus infection and illness in humans. Antimicrob Agents Chemother 1994, 38:1178-1181.
34. Walker J.B., Hussey E.K., Treanor J.J., Montalvo A., Hayden F.G. Effects of the neuraminidase inhibitor zanamivir on otologic manifestations of experimental human influenza. J Infect Dis 1997, 176:1417-1422.
35. Douglas R.G., Betts R.F., Simons R.L., Hogan P.W., Roth F.K. Evaluation of a topical interferon inducer in experimental influenza infection in volunteers. Antimicrob Agents Chemother 1975, 8:684-687.
36. Fries L.F., Dillon S.B., Hildreth J.E., Karron R.A., Funkhouser A.W., Friedman C.J., et al. Safety and immunogenicity of a recombinant protein influenza A vaccine in adult human volunteers and protective efficacy against wild-type H1N1 virus challenge. J Infect Dis 1993, 167:593-601.
37. Youngner J.S., Treanor J.J., Betts R.F., Whitaker-Dowling P. Effect of simultaneous administration of cold-adapted and wild-type influenza A viruses on experimental wild-type influenza infection in humans. J Clin Microbiol 1994, 32:750-754.
38. Keitel WA, Couch RB, Cate TR, Six HR, Baxter BD. Cold recombinant influenza B/Texas/1/84 vaccine virus (CRB87): attenuation, immunogenicity and efficacy and homotypic challenge. J Infect Dis 1990;161:22-6.
39. Ison M.G., Campbell V., Rembold C., Dent J., Hayden F.G. Cardiac findings during uncomplicated acute influenza in ambulatory adults. Clin Infect Dis 2005, 40:415-422. 10.1086/427282.
40. Carrat F., Vergu E., Ferguson N.M., Lemaitre M., Cauchemez S., Leach S., et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 2008, 167:775-785. 10.1093/aje/kwm375.
41. Wilkinson T.M., Li C.K., Chui C.S., Huang A.K., Perkins M., Liebner J.C., et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012, 18:274-280. 10.1038/nm.2612.
42. Halonen P., Mujunen R., Mantyjarvi R. On the preventive effect of amantadine hydrochloride in influenza and other respiratory viral infections. Sotilaslaak Aikak 1965, 40:130-137.
43. Stanley ED, Muldoon RE, Akers LW, Jackson GG. Evaluation of antiviral drugs: the effect of amantadine on influenza in volunteers. Ann N Y Acad Sci 1965;130:44-51.
44. Lee S.H., Dobson P.R., van Rooyen C.E. Antiviral substances: 6-aminonicotinamide and 1-adamantanamine hydrochloride. Chemotherapy 1966, 11:163-177.
45. Oker-Blom N., Hovi T., Leinikki P., Palosuo T., Pettersson R., Suni J. Protection of man from natural infection with influenza A2 Hong Kong virus by amantadine: a controlled field trial. Br Med J 1970, 3:676-678.
46. Dawkins A.T., Gallager L.R., Togo Y., Hornick R.B., Harris B.A. Studies on induced influenza in man: II. double-blind study designed to assess the prophylactic efficacy of an analogue of amantadine hydrochloride. JAMA 1968, 203:1095-1099.
47. Skoner D.P., Gentile D.A., Patel A., Doyle W.J. Evidence for cytokine mediation of disease expression in adults experimentally infected with influenza A virus. J Infect Dis 1999, 180:10-14. 10.1086/314823.
48. Li F., Ma C., Wang J. Inhibitors targeting the influenza virus hemagglutinin. Curr Med Chem 2015, 22:1361-1382.
49. Van Noorden R. Flu Drug Stockpiling Reported to Be a Waste of Money. Nature Pharmaceuticals. April 12 2014. http://www.scientificamerican.com/article/flu-drug-stockpiling-reported-to-be-a-waste-of-money/.
50. Gubareva L.V., Kaiser L., Matrosovich M.N., Soo-Hoo Y., Hayden F.G. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 2001, 183:523-531. 10.1086/318537.
51. Beare A.S., Hall T.S., Tyrrell D.A. Protection of volunteers against challenge with A-Hong Kong-68 influenza virus by a new adamantane compound. Lancet 1972, 1:1039-1040.
52. Treanor JJ, Betts RF, Erb SM, Roth FK, Dolin R. Intranasally administered interferon as prophylaxis against experimentally induced influenza A virus infection in humans. J Infect Dis 1987;156:379-83.
53. Tannock G.A., Gillett S.M., Gillett R.S., Barry R.D., Hensley M.J., Herd R., et al. A study of intranasally administered interferon A (rIFN-alpha 2A) for the seasonal prophylaxis of natural viral infections of the upper respiratory tract in healthy volunteers. Epidemiol Infect 1988, 101:611-621.
54. Title 21-Food and drugs, Chapter I-Food and Drug Administration, Department Of Health And Human Services, Subchapter F-Biologics 21CFR600.3. FDA 2015. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=600.3. (accessed March 29, 2015).
55. Darton T.C., Blohmke C.J., Moorthy V.S., Altmann D.M., Hayden F.G., Clutterbuck E.A., et al. Design, recruitment, and microbiological considerations in human challenge studies. Lancet Infect Dis 2015, 15:840-851. 10.1016/S1473-309900068-7.
56. Miller F.G., Grady C. The ethical challenge of infection-inducing challenge experiments. Clin Infect Dis 2001, 33:1028-1033. 10.1086/322664.
57. Lynch H.F. The rights and wrongs of intentional exposure research: contextualising the Guatemala STD inoculation study. J Med Ethics 2012, 38:513-515. 10.1136/medethics-2011-100379.
58. Hope T., McMillan J. Challenge studies of human volunteers: ethical issues. J Med Ethics 2004, 30:110-116.
59. Chang H.L., Hsu J.F., Tsai Y.M., Lin S.Y., Kuo H.F., Yang C.J. Acute respiratory distress syndrome and acute myocarditis developed in a previously healthy adult with influenza B. BMC Pulm Med 2016, 16:1. 10.1186/s12890-015-0163-3.
60. Memoli M.J., Czajkowski L., Reed S., Athota R., Bristol T., Proudfoot K., et al. Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study. Clin Infect Dis 2015, 60:693-702. 10.1093/cid/ciu924.
61. Kalil J.A., Halperin S.A., Langley J.M. Human challenge studies: a review of adequacy of reporting methods and results. Future Microbiol 2012, 7:481-495. 10.2217/fmb.12.15.
62. Phillpotts RJ, Higgins PG, Tillman JS, Tyrrell DA, Freestone DS, Shepherd WM. Intranasal lymphoblastoid interferon ('Wellferon') prophylaxis against rhinovirus and influenza virus in volunteers. J Interferon Res 1984;4:535-41.
63. Kaiser L., Henry D., Flack N.P., Keene O., Hayden F.G. Short-term treatment with zanamivir to prevent influenza: results of a placebo-controlled study. Clin Infect Dis 2000, 30:587-589. 10.1086/313696.
64. Monto A.S., Robinson D.P., Herlocher M.L., Hinson J.M., Elliott M.J., Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999, 282:31-35.